These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 31255411)

  • 21. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Connor YD; Miao D; Lin DI; Hayne C; Howitt BE; Dalrymple JL; DeLeonardis KR; Hacker MR; Esselen KM; Shea M
    Gynecol Oncol; 2020 Apr; 157(1):106-114. PubMed ID: 31954538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
    Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
    Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
    Ramalingam P; Croce S; McCluggage WG
    Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.
    Kohashi K; Yamamoto H; Kumagai R; Yamada Y; Hotokebuchi Y; Taguchi T; Iwamoto Y; Oda Y
    Mod Pathol; 2014 Jun; 27(6):832-9. PubMed ID: 24287458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
    Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
    Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
    Rizzo D; Fréneaux P; Brisse H; Louvrier C; Lequin D; Nicolas A; Ranchère D; Verkarre V; Jouvet A; Dufour C; Edan C; Stéphan JL; Orbach D; Sarnacki S; Pierron G; Parfait B; Peuchmaur M; Delattre O; Bourdeaut F
    Am J Surg Pathol; 2012 Jul; 36(7):964-72. PubMed ID: 22614000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors?
    Renard C; Pissaloux D; Decouvelaere AV; Bourdeaut F; Ranchère D
    Cancer Genet; 2014 Sep; 207(9):384-9. PubMed ID: 25053104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
    Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
    Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
    Nakayama RT; Pulice JL; Valencia AM; McBride MJ; McKenzie ZM; Gillespie MA; Ku WL; Teng M; Cui K; Williams RT; Cassel SH; Qing H; Widmer CJ; Demetri GD; Irizarry RA; Zhao K; Ranish JA; Kadoch C
    Nat Genet; 2017 Nov; 49(11):1613-1623. PubMed ID: 28945250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation. a pilot study.
    Kupryjańczyk J; Dansonka-Mieszkowska A; Moes-Sosnowska J; Plisiecka-Hałasa J; Szafron L; Podgórska A; Rzepecka IK; Konopka B; Budziłowska A; Rembiszewska A; Grajkowska W; Spiewankiewicz B
    Pol J Pathol; 2013 Dec; 64(4):238-46. PubMed ID: 24375037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report of Small Cell Carcinoma of the Ovary, Hypercalcemic Type (Ovarian Rhabdoid Tumor) with
    Simões MFE; da Costa AABA; Silva TN; Fernandes L; Bovolim G; Torrezan GT; Carraro DM; Baiocchi G; Menezes ANO; Santana Dos Santos E; De Brot L
    Curr Oncol; 2022 Jan; 29(2):411-422. PubMed ID: 35200537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome.
    Hasselblatt M; Thomas C; Federico A; Nemes K; Johann PD; Bison B; Bens S; Dahlum S; Kordes U; Redlich A; Lessel L; Pajtler KW; Mawrin C; Schüller U; Nolte K; Kramm CM; Hinz F; Sahm F; Giannini C; Penkert J; Kratz CP; Pfister SM; Siebert R; Paulus W; Kool M; Frühwald MC
    Am J Surg Pathol; 2022 Sep; 46(9):1277-1283. PubMed ID: 35446794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on SWI/SNF-related gynecologic mesenchymal neoplasms: SMARCA4-deficient uterine sarcoma and SMARCB1-deficient vulvar neoplasms.
    Howitt BE; Folpe AL
    Genes Chromosomes Cancer; 2021 Mar; 60(3):190-209. PubMed ID: 33252159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.
    Perret R; Chalabreysse L; Watson S; Serre I; Garcia S; Forest F; Yvorel V; Pissaloux D; Thomas de Montpreville V; Masliah-Planchon J; Lantuejoul S; Brevet M; Blay JY; Coindre JM; Tirode F; Le Loarer F
    Am J Surg Pathol; 2019 Apr; 43(4):455-465. PubMed ID: 30451731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate: report of a unique case with emphasis on diagnostic implications.
    Xu W; Dong H; Ru G; Zhao M
    Diagn Pathol; 2022 Feb; 17(1):22. PubMed ID: 35125107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
    Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [SMARCA4-deficient thoracic tumors: A new entity].
    Decroix E; Leroy K; Wislez M; Fournel L; Alifano M; Damotte D; Mansuet-Lupo A
    Bull Cancer; 2020 Jan; 107(1):41-47. PubMed ID: 31916995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hereditary SWI/SNF complex deficiency syndromes.
    Agaimy A; Foulkes WD
    Semin Diagn Pathol; 2018 May; 35(3):193-198. PubMed ID: 29397238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.
    Hasselblatt M; Gesk S; Oyen F; Rossi S; Viscardi E; Giangaspero F; Giannini C; Judkins AR; Frühwald MC; Obser T; Schneppenheim R; Siebert R; Paulus W
    Am J Surg Pathol; 2011 Jun; 35(6):933-5. PubMed ID: 21566516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.